• 한국작물학회:학술대회논문집
• /
• 한국작물학회 2017년도 9th Asian Crop Science Association conference
• /
• pp.350-350
• /
• 2017

The study was conducted to evaluate differences of growth characteristics of rice cultivated in two different regions (Cheonan and Jeonju). It focused on nutritional composition and anti-nutritional factors of rice straw produced from 21 rice varieties including GM rice (Iksan 483). The range of general nutrition ingredient is that crude was 0.97 ~ 3.2 %, carbohydrate was 67.45 ~ 80.01 %, crude protein was 1.46 ~ 4.81 %, crude ash was 6.52 ~ 18.96 %, crude fiber was 25.77 ~ 40.02 %, NDF was 51.84 ~ 67.77 %, ADF was 27.11 ~ 40.44 %, calcium was 0.49 ~ 5.18 mg/g and phosphorous was 0.26 ~ 2.77 mg/g. The general nutritional contents of GM rice were included above range. The range of phytic acid of rice straws cultivated in Cheonan and Jeonju was 0 ~ 0.056 mg/ml and 0 ~ 0.059 mg/ml, respectively. The phytic acid content of GM was 0.033 mg/ml, which was in the range of the content of rice straw in Cheonan and Jeonju. The range of trypsin inhibitor of rice straws cultivated in Cheonan and Jeonju was 0.061 ~ 0.461 TIU/mg and 0 ~ 1.278 TIU/mg, respectively. The trypsin acid content of GM was 0.461 TIU/mg, which was in the range of the content of rice straw in Cheonan and Jeonju. In addition, we investigated microbial community from each soil sample by using metagenomics sequencing based on rRNA microbial diversity in order to inspect indirect changes of soil environment with cultivation of GM rice. Metagenomics analysis was carried out using soil samples cultivated with GM and non-GM rice for before transplanting, young panicle differentiation stage, heading stage, and ripening stage. Beta diversity of microbial community in both soil environments were calculated by using Bray-Curtis distance method and showed low value with an average of 0.24 (dissimilarity = 1). As a result, it was confirmed that the cultivation of GM does not give a significant effect on the change of microbial composition in soil. Therefore, Our study demonstrates that there is no difference in the composition of soil microorganism due to GM and non-GM rice.

• Biomolecules & Therapeutics
• /
• 제19권2호
• /
• pp.187-194
• /
• 2011

Atherosclerosis and post-angiography restenosis are associated with intimal thickening and concomitant vascular smooth muscle cell (VSMC) proliferation. Obovatol, a major biphenolic component isolated from the Magnolia obovata leaf, is known to have anti-inflammatory and anti-tumor activities. The goal of the present study was to enhance the inhibitory effects of obovatol to improve its potential as a preventive or therapeutic agent in atherosclerosis and restenosis. Platelet-derived growth factor (PDGF)-BB-induced proliferation of rat aortic smooth muscle cells (RASMCs) was examined in the presence or absence of a newly synthesized obovatol derivative, OD78. The observed anti-proliferative effect of OD78 was further investigated by cell counting and [$^3H$]-thymidine incorporation assays. Treatment with 1-4 ${\mu}M$ OD78 dose-dependently inhibited the proliferation and DNA synthesis of 25 ng/ml PDGF-BB-stimulated RASMCs. Accordingly, OD78 blocked PDGF-BB-induced progression from the $G_0/G_1$ to S phase of the cell cycle in synchronized cells. OD78 decreased the expression levels of CDK4, cyclin E, and cyclin D1 proteins, as well as the phosphorylation of retinoblastoma protein and proliferating cell nuclear antigen; however, it did not change the CDK2 expression level. In addition, OD78 inhibited downregulation of the cyclin-dependent kinase inhibitor (CKI) $p27^{kip1}$. However, OD78 did not affect the CKI $p21^{cip1}$ or phosphorylation of early PDGF signaling pathway. These results suggest that OD78 may inhibit PDGF-BB-induced RASMC proliferation by perturbing cell cycle progression, potentially through $p27^{kip1}$ pathway activation. Consequently, OD78 may be developed as a potential anti-proliferative agent for the treatment of atherosclerosis and angioplasty restenosis.

• Weed & Turfgrass Science
• /
• 제7권2호
• /
• pp.166-169
• /
• 2018

경남지역 제초제 저항성 피의 발생현황과 저항성 정도를 알아보기 위하여 벼 재배 논에서 100개체의 피 종자를 수집하여 ACCase 저해제인 cyhalofop-butyl에 대한 약량반응 실험을 수행한 결과, 수집한 피의 7%가 저항성으로 조사되었다. 선발된 감수성 5개체의 $GR_{50}$값은 평균 $147g\;a.i.\;ha^{-1}$로 나타났고, 함양 지역의 저항성 개체의 $GR_{50}$값은 $738g\;a.i.\;ha^{-1}$ 로 R/S (ratio of resistance to sensitivity)값은 5.01배로 나타났다. 현재 경남지역에서의 저항성 피의 발생 수준은 낮은 것으로 나타났지만, 저항성 피의 확산을 지연시키거나 막기 위해서는 주기적인 저항성 피의 모니터링과 체계적인 저항성 잡초 관리방안을 마련하여 수행할 필요가 있다.

• 상하수도학회지
• /
• 제21권6호
• /
• pp.727-735
• /
• 2007

The use of water by cities is increasing owing to industrialization, the concentration of population, and the enhancement of the standard of living. Accordingly, the amount of waste water is also increasing, and the degree of pollution of the water system is rising. In order to solve this problem, it is necessary to remove organisms and suspended particles as well as the products of eutrophication such as nitrates and phosphates. This study developed a high-end treatment engineering solution with maximum efficiency and lower costs by researching and developing a advanced treatment engineering solution with the use of Biosorption. As a result, the study conducted a test with a $50m^3/day$ Pilot Scale Plant by developing treatment engineering so that only the secondary treatment satisfies the standard of water quality and which provided optimal treatment efficiency along with convenient maintenance and management. The removal of organisms, which has to be pursued first for realizing nitrification during the test period, was made in such a way that there would be no oxidation by microorganisms in the reactor while preparing oxygen as an inhibitor for the growth of microorganism in the course of moving toward the primary settling pond. The study introduced microorganisms in the endogeneous respiration stage to perform adhesion, absorption, and filtering by bringing them into contact with the inflowing water with the use of a sludge returning from the secondary settling pond. Also a test was conducted to determine how effective the microorganisms are as an inner source of carbon. The HRT(Hydraulic Retention Time) in the nitrification tank (aerobic tank) could be reduced to two hours or below, and the stable treatment efficiency of the process using the organisms absorbed in the NAR reactor as a source of carbon could be proven. Also, given that the anaerobic condition of the pre-treatment tank becomes basic in the area of phosphate discharge, it was found that there was excellent efficiency for the removal of phosphate when the pre-treatment tank induced the discharge of phosphate and the polishing reactor induced the uptake of phosphate. The removal efficiency was shown to be about 94.4% for $BOD_5$. 90.7% for $COD_{Cr}$ 84.3% for $COD_{Mn}$, 96.0% for SS, 77.3% for TN, and 96.0% for TP.

• Tuberculosis and Respiratory Diseases
• /
• 제61권2호
• /
• pp.150-156
• /
• 2006

배 경: 최근 폐암 환자에서 사용하는 표적치료 항암약물인 gefitinib (Iressa)은 종양세포의 표피성장인자 수용체의 티로신 키나아제 활동을 선택적으로 억제하여 종양 세포의 성장에 관여하는 신호를 차단함으로써 치료효과를 나타낸다. Gefitinib 복용에 의한 피부 부작용으로 여드름양 발진, 피부 건조증, 모발 변화 등이 알려져 있다. 대상 및 방법: 2004년 10월부터 2005년 9월까지 화순전남대병원에서 비소세포 폐암으로 진단받고 gefitinib을 복용 중인 환자들 중 피부 부작용이 발생하여 피부과에 의뢰된 환자 23명을 대상으로 임상 양상을 분석하였다. 결 과: 나이는 23-72세였고, 비소세포 폐암의 종류는 선암 17명, 편평상피세포 폐암 5명이었고, 여자 6명, 남자 17명이었다. 가장 흔한 부작용은 여드름양 발진으로 15명(65.2%)에서 발생하였으며, 주로 두피, 얼굴, 가슴, 등 부위에 무증상의 홍반성 구진으로 나타나며 대부분 gefitinib 복용 1달 이내에 발생하였다. 여드름양 발진의 빈도는 gefitinib 치료에 대한 반응과 유의한 상관관계를 보이지 않았고, 조직 형에 따른 차이도 관찰되지 않았다. 피부 소양증은 9명(39.1%)에서 발생하였으며 경도의 전신 소양증이 가장 많았고, 특히 눈 주변의 소양증을 호소하였다. 인설을 동반한 피부 건조증이 6명(26.1%)에서 발생하였고, 손발바닥의 홍반과 표피 박탈이 5명(21.7%), 손톱이나 발톱주변에 조갑주위염이 5명(21.7%)에서 발생하였다. 드물게 모발이 부러지거나 겨드랑이, 오금에 간찰진이 발생하였다. 결 론: 본 연구에서 gefitinib에 의한 다양한 피부 부작용들을 관찰할 수 있었다. Gefitinib을 처방하는 의사들은 피부 부작용에 대한 관심이 필요하며 환자들에게 피부 관리에 대한 교육과 필요한 경우 피부과 의사와 함께 피부 부작용을 치료함으로써 부작용을 경감시킬 수 있었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권3호
• /
• pp.909-914
• /
• 2012

Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities. This retrospective analysis was conducted to compare the efficacy of gefitinib alone with gefitinib plus concomitant WBRT in treatment of BM from NSCLC. Methods: We retrospectively reviewed 90 patients with BM from NSCLC who received gefitinib alone (250mg/day, gefitinib group) or with concomitant WBRT (40Gy/20f/4w, gefitinib-WBRT group) between September 2005 and September 2009 at Sun Yat-Sen University Cancer Center. Forty-five patients were in each group. Results: The objective response rate of BM was significantly higher in gefitinib-WBRT group (64.4%) compared with gefitinib group (26.7%, P<0.001). The disease control rate of BM was 71.1% in gefitinib-WBRT group and 42.2% in gefitinib group (P=0.006). The median time to progression of BM was 10.6 months in gefitinib-WBRT group and 6.57 months in gefitinib group (P<0.001). The median overall survival(OS) of gefitinib-WBRT and gefitinib alone group was 23.40 months and 14.83 months, respectively (HR, 0.432, P=0.002). Conclusion: Gefitinib plus concomitant WBRT had higher response rate of BM and significant improvement in OS compared with gefitinib alone in treatment of BM from NSCLC.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권10호
• /
• pp.5177-5182
• /
• 2012

Purpose: To compare the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitormonotherapy (EFGR-TKIs: gefitinib or erlotinib) with standard second-line chemotherapy (single agent docetaxel or pemetrexed) in previously treated advanced non-small-cell lung cancer (NSCLC). Methods: We systematically searched for randomized clinical trials that compared EGFR-TKI monotherapy with standard second-line chemotherapy in previously treated advanced NSCLC. The end points were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), 1-year survival rate (1-year SR) and grade 3 or 4 toxicities. The pooled hazard ratio (HR) or risk ratio (RR), with their corresponding 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. Results: Eight randomized controlled trials (totally 3218 patients) were eligible. Our meta-analysis results showed that EGFR-TKIs were comparable to standard second-line chemotherapy for advanced NSCLC in terms of overall survival (HR 1.00, 95%CI 0.92-1.10; p=0.943), progression-free survival (HR 0.90, 95%CI 0.75-1.08, P=0.258) and 1-year-survival rate (RR 0.97, 95%CI 0.87-1.08, P=0.619), and the overall response rate was higher in patients who receiving EGFR-TKIs(RR 1.50, 95%CI 1.22-1.83, P=0.000). Sub-group analysis demonstrated that EGFR-TKI monotherapy significantly improved PFS (HR 0.73, 95%CI: 0.55-0.97, p=0.03) and ORR (RR 1.96, 95%CI: 1.46-2.63, p=0.000) in East Asian patients, but it did not translate into increase in OS and 1-year SR. Furthermore, there were fewer incidences of grade 3 or 4 neutropenia, febrile neutropenia and neutrotoxicity in EGFR-TKI monotherapy group, excluding grade 3 or 4 rash. Conclusion: Both interventions had comparable efficacy as second-line treatments for patients with advanced NSCLC, and EGFR-TKI monotherapy was associated with less toxicity and better tolerability. Moreover, our data also demonstrated that EGFR-TKImonotherapy tended to be more effective in East Asian patients in terms of PFS and ORR compared with standard second-line chemotherapy. These results should help inform decisions about patient management and design of future trials.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권10호
• /
• pp.5291-5298
• /
• 2012

Beta-asarone is one of the main bioactive constituents in traditional Chinese medicine Acorus calamu. Previous studies have shown that it has antifungal and anthelmintic activities. However, little is known about its anticancer effects. This study aimed to determine inhibitory effects on LoVo colon cancer cell proliferation and to clarify the underlying mechanisms in vitro and in vivo. Dose-response and time-course anti-proliferation effects were examined by MTT assay. Our results demonstrated that LoVo cell viability showed dose- and time-dependence on ${\beta}$-asarone. We further assessed anti-proliferation effects as ${\beta}$-asarone-induced apoptosis by annexin V-fluorescein isothiocyanate/propidium iodide assay usinga flow cytometer and observed characteristic nuclear fragmentation and chromatin condensation of apoptosis by microscopy. Moreover, we found the apoptosis to be induced through the mitochondrial/caspase pathway by decreasing mitochondrial membrane potential (MMP) and reducing the Bcl-2-to-Bax ratio, in addition to activating the caspase-9 and caspase-3 cascades. Additionally, the apoptosis could be inhibited by a pan-caspase inhibitor, carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (Z-VAD-FMK). When nude mice bearing LoVo tumor xenografts were treated with ${\beta}$-asarone, tumor volumes were reduced and terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assays of excised tissue also demonstrated apoptotic changes. Taken together, these findings for the first time provide evidence that ${\beta}$-asarone can suppress the growth of colon cancer and the induced apoptosis is possibly mediated through mitochondria/caspase pathways.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권2호
• /
• pp.657-662
• /
• 2014

Background: The epidermal growth factor receptor (EGFR) mutation status of lung cancer is important because it means that EGFR-tyrosine kinase inhibitor treatment is indicated. The purpose of this prospective study is to determine whether EGFR mutation status could be identified with reference to preoperative factors. Materials and Methods: One hundred-forty eight patients with lung cancer (111 adenocarcinomas, 25 squamous cell carcinomas and 12 other cell types) were enrolled in this study. The EGFR mutation status of each lung cancer was analyzed postoperatively. Results: There were 58 patients with mutant EGFR lung cancers (mutant LC) and 90 patients with wild-type EGFR lung cancers (wild-type LC). There were significant differences in gender, smoking status, maximum tumor diameter in chest CT, type of tumor shadow, clinical stage between mutant LC and wild-type LC. EGFR mutations were detected only in adenocarcinomas. Maximum standardized uptake value (SUVmax:$3.66{\pm}4.53$) in positron emission tomography-computed tomography of mutant LC was significantly lower than that ($8.26{\pm}6.11$) of wild-type LC (p<0.0001). Concerning type of tumor shadow, the percentage of mutant LC was 85.7% (6/7) in lung cancers with pure ground glass opacity (GGO), 65.3%(32/49) in lung cancers with mixed GGO and 21.7%(20/92) in lung cancers with solid shadow (p<0.0001). For the results of discriminant analysis, type of tumor shadow (p=0.00036) was most significantly associated with mutant EGFR. Tumor histology (p=0.0028), smoking status (p=0.0051) and maximum diameter of tumor shadow in chest CT (p=0.047) were also significantly associated with mutant EGFR. The accuracy for evaluating EGFR mutation status by discriminant analysis was 77.0% (114/148). Conclusions: Mutant EGFR is significantly associated with lung cancer with pure or mixed GGO, adenocarcinoma, never-smoker, smaller tumor diameter in chest CT. Preoperatively, EGFR mutation status can be identified correctly in about 77 % of lung cancers.

• 한국미생물·생명공학회지
• /
• 제32권2호
• /
• pp.142-148
• /
• 2004

에리스로포이에틴은 인간 적혈구분화의 조절인자로 작용한다. 유전자 재조합 인간에리스로포이에틴(rhEPO)은 동물세포에서 생산되고 있는 재조합 당단백질의 하나이며 당쇄부분이 전체 분자량의 40％를 차지한다. 시알산 함량은 체내약물 투여 지속기간과 직접적인 연관이 있어 시알산 함량은 의약용 당단백질의 중요한 성질로 여겨진다. 본 연구에서는 CHO세포 배양액에 시알산 생합성 전구물질인 N-acetylmannosamine(ManNAc)과 sialidase 저해제인 2-deoxy-2,3-hyo-N-acetylneuraminic acid(NeuAc2en)를 첨가하여 rhEPO의 sialic acid함량을 증가시킬 수 있었다. 특히, 배양액에 20 mM ManNAc/0.5 mM NeuAc2en를 첨가할 때 대조구에 비하여 약 10배의 시알산 함량이 증가하였으며 세포성장이나 배양액의 rhEPO생산량에는 영향이 없었다. rhEPO의 정제시 시알산 함량이 11∼15％인 다당쇄 rhEPO분획을 얻었으며, 배양액 내에 20 mM ManNAc와 0.5 mM NeuAc2en를 동시에 첨가함으로 대조구에 비하여 시말산함량이 높은다당쇄 rhEPO의 생산성이 50％ 증가하였다.